Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
Financial Results:
Gland Pharma Ltd reported Revenues for Q3FY24 of ₹1,545.00 Crores up from ₹938.00 Crore year on year, a rise of 64.71%.
Total Expenses for Q3FY24 of ₹1,299.00 Crores up from ₹690.00 Crores year on year, a rise of 88.26%.
Consolidated Net Profit of ₹192.00 Crores down 17.24% from ₹232.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹11.65, down 17.26% from ₹14.08 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.